Efficacy of a Viral Load-Based, Risk-Adapted, Preemptive Treatment Strategy for Prevention of Cytomegalovirus Disease after Hematopoietic Cell Transplantation
Open Access
- 8 June 2012
- journal article
- research article
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 18 (11) , 1687-1699
- https://doi.org/10.1016/j.bbmt.2012.05.015
Abstract
No abstract availableKeywords
Funding Information
- Joel Meyers Endowment Fund
- Infectious Disease Society of America Education and Research Foundation
- National Foundation for Infectious Diseases Astellas Postdoctoral Fellowship in Transplant Infectious Diseases
- Viropharma/ASBMT New Investigator Award
- National Institutes of Health (CA18029, CA15704, CA78902, HL093294, HL36444, NHLBI K23HL096831, NIAID K24AI071113, NIAID K24HL093294)
- Chimerix, Merck
- Viropharma
- GlaxoSmithKline
- Gilead
- AiCuris
- Agenus
- Vical
- Chimerix
This publication has 42 references indexed in Scilit:
- Intensive strategy to prevent CMV disease in seropositive umbilical cord blood transplant recipientsBlood, 2011
- An International Comparison of Current Strategies to Prevent Herpesvirus and Fungal Infections in Hematopoietic Cell Transplant RecipientsTransplantation and Cellular Therapy, 2011
- Cytomegalovirus glycoprotein-B vaccine with MF59 adjuvant in transplant recipients: a phase 2 randomised placebo-controlled trialThe Lancet, 2011
- Reduced Mortality after Allogeneic Hematopoietic-Cell TransplantationNew England Journal of Medicine, 2010
- Guidelines for Preventing Infectious Complications among Hematopoietic Cell Transplantation Recipients: A Global PerspectiveTransplantation and Cellular Therapy, 2009
- The impact of a change in antibacterial prophylaxis from ceftazidime to levofloxacin in allogeneic hematopoietic cell transplantationBone Marrow Transplantation, 2009
- Effect of Conditioning Regimen Intensity on CMV Infection in Allogeneic Hematopoietic Cell TransplantationTransplantation and Cellular Therapy, 2009
- Revised Definitions of Invasive Fungal Disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus GroupClinical Infectious Diseases, 2008
- Lipopolysaccharide binding protein promoter variants influence the risk for Gram-negative bacteremia and mortality after allogeneic hematopoietic cell transplantationBlood, 2008
- Relapse risk in patients with malignant diseases given allogeneic hematopoietic cell transplantation after nonmyeloablative conditioningBlood, 2007